文献速递妇科产科

BRCA突变携带者降低风险输卵管卵巢切除术中偶然发现的卵巢癌结局

Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers.
PubMed 文献 · Gynecol Oncol · 2021-03-10

该研究在三级转诊中心回顾性分析了2005年至2017年间548例接受降低风险输卵管卵巢切除术的BRCA突变患者,其中26例(4.7%)偶然发现隐匿性浸润性卵巢癌。所有肿瘤均为高级别浆液性癌,中位随访67.3个月,早期患者无复发,5年无进展生存率为72%,5年疾病特异性生存率为96%。

要点

  • BRCA突变者RRSO时隐匿性卵巢癌发生率约4.7%
  • 所有隐匿癌均为高级别浆液性癌,多数为早期
  • 早期患者无复发,5年疾病特异性生存率达96%

核心结论

  • BRCA突变患者RRSO时约5%偶然发现隐匿性浸润性卵巢癌,多数早期患者预后良好,与基于分期的预期一致。

研究设计与样本

  • 回顾性队列研究,纳入2005年1月至2017年5月在三级转诊中心接受RRSO的548例BRCA突变患者,排除术前怀疑恶性的病例。

主要发现

  • 548例中26例(4.7%)发现隐匿性浸润性卵巢癌,中位年龄55岁(范围42-75)。
  • 15例(58%)为BRCA1突变,9例(34%)为BRCA2突变,2例(8%)同时携带两种突变。
  • 所有肿瘤均为高级别浆液性癌:10例(38%)为I期,8例(31%)为II期,8例(31%)为III期。
  • 24例(92%)接受了辅助铂/紫杉类化疗。
  • 中位随访67.3个月(范围28-166),I期患者无复发,II期2例、III期6例复发。

临床怎么用

  • BRCA突变患者行RRSO时应规范取材以发现隐匿癌。
  • 术后根据分期和病理决定辅助化疗,早期患者预后良好。

局限性

  • 回顾性单中心设计,样本量较小(26例隐匿癌),随访时间有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Prior data suggested that women with incidentally detected occult invasive ovarian cancer (OIOC) at the time of risk-reducing salpingo-oophorectomy (RRSO) for BRCA mutation may have poorer prognoses than would be expected based on disease stage. We sought to evaluate prevalence and outcomes of patients with OIOC in a tertiary referral center. METHODS: Patients with BRCA mutation undergoing RRSO from 01/2005 to 05/2017 were identified, and their records reviewed. Women with incidentally detected OIOC were included; those with clinical features raising preoperative suspicion for malignancy were excluded. RESULTS: 548 patients with BRCA mutation who underwent RRSO were identified. 26 (4.7%) had an OIOC (median age 55 years; range 42-75); 15(58%) patients, BRCA1; 9(34%), BRCA2; 2(8%) had a mutation in both genes. All OIOCs were high-grade serous: 10 (38%) Stage I; 8 (31%) Stage II; 8(31%) Stage III. 24(92%) patients received adjuvant platinum/taxane therapy. Of Stage III patients, 4 (50%) were identified intraoperatively; the remaining 4 (50%) had microscopic nodal disease on final pathology only. At median follow-up of 67.3 months (28-166) no Stage I patients have recurred; 2 Stage II and 6 Stage III patients recurred. 5-year progression-free survival (PFS) was 72% (95%CI, 50.2-85.7%); median PFS for the cohort was 129 months (95%CI, 75.3-not estimable). 5-year disease-specific survival (DSS) was 96% (95%CI, 76-99%); median DSS not reached. CONCLUSION: Consistent with prior reports, almost 5% of patients had an OIOC at RRSO. The majority with early-stage disease had excellent PFS and DSS outcomes, as would be expected based on disease stage.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Cowan R, Nobre SP, Pradhan N, et al. Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers. Gynecol Oncol. 2021. PMID: 33712278. doi:10.1016/j.ygyno.2021.02.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。